Sutro Biopharma
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Sutro Biopharma sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Sutro Biopharma: 6 sponsored US clinical trials, 1 recruiting.
Sutro Biopharma sponsors 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Head and Neck Squamous Cell Carcinoma (HNSCC), with 1 trials.
Upper-quartile sponsor footprint
Sutro Biopharma sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
NCT07227168
Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML
NCT06679582
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
NCT05870748
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
NCT05200364
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
NCT03748186
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
NCT03424603
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 1 |
What is open in the Sutro Biopharma pipeline
1 recruiting of 6 indexed (17% open); 2 completed (33%).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Head and Neck Squamous Cell Carcinoma (HNSCC) (1 trial), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sutro Biopharma: open-pipeline peers nationwide
Peers matched on 6 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Sutro Biopharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Angiodynamics · 17% recruiting · 12 trials
Related
What to do with this Sutro Biopharma page
6 registered trials is a research-attention snapshot, not an endorsement of Sutro Biopharma or any single study.
- 1 of Sutro Biopharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Head and Neck Squamous Cell Carcinoma (HNSCC) is the condition Sutro Biopharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Head and Neck Squamous Cell Carcinoma (HNSCC) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Sutro Biopharma pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.